GSK (GSK) Status Update summary

Oncology Portfolio Growth and Strategy

• Focus on oncology, hematology, gynecologic cancers, and solid tumors, with a strong pipeline in ADCs, immunotherapy, and targeted small molecules, including transformative assets like Blenrep, Jemperli, Zejula, and Ojjaara.

• Blenrep is highlighted as a potential multi-blockbuster for multiple myeloma, with significant PFS and OS benefits in DREAMM-7 and DREAMM-8 trials, and manageable ocular toxicity through dose adjustments.

• Ojjaara launched successfully in the US and EU for myelofibrosis, showing rapid uptake and blockbuster potential in both first and second line settings.

• Zejula continues to grow in ovarian cancer and is being explored in glioblastoma, with promising phase II data and phase III trials underway.

• Jemperli demonstrates strong efficacy in endometrial, rectal, and colorectal cancers, with expansion into other solid tumors and combinations.

Clinical Data and Product Differentiation

• Blenrep combinations in DREAMM-7 and DREAMM-8 show superior PFS and response rates versus standard regimens, with consistent benefits across high-risk and refractory subgroups.

• Ocular adverse events with Blenrep are mostly reversible and manageable, with extended dosing intervals maintaining efficacy and improving tolerability.

• Jemperli achieves 100% complete response in dMMR rectal cancer in a collaborative study, supporting its potential to replace standard treatments.

• ADCs GSK 584 (B7-H4) and GSK 227 (B7-H3) show promising early clinical activity and are positioned for rapid development in gynecological and other solid tumors, with proof-of-concept studies starting in H2 2024.

• Proprietary combinations and novel strategies, especially with immuno-oncology and ADCs, underpin future ambitions.

Market Positioning and Future Catalysts

• Blenrep is expected to be differentiated among anti-BCMA agents due to efficacy, convenience, and broad patient eligibility, with filings planned in all major markets by year-end 2024.

• Key oncology data readouts and regulatory filings for Blenrep and Jemperli are expected between 2024 and 2026, supporting future growth.

• Ongoing efforts to simplify Blenrep dosing and minimize ophthalmology requirements aim to enhance community adoption.

• Jemperli and TIGIT inhibitor belrestatug are advancing in lung and head and neck cancers, with phase III trials planned based on positive interim data.

• Strategic focus on combinations, platform studies, and capital allocation to maximize return and long-term growth across the oncology portfolio.